Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion.

Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A.

Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25276. [Epub ahead of print]

PMID:
30014505
2.

Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis.

Proudfoot M, van Ede F, Quinn A, Colclough GL, Wuu J, Talbot K, Benatar M, Woolrich MW, Nobre AC, Turner MR.

Clin Neurophysiol. 2018 Jul;129(7):1479-1489. doi: 10.1016/j.clinph.2018.03.019. Epub 2018 Apr 6.

PMID:
29678369
3.

Increased cerebral functional connectivity in ALS: A resting-state magnetoencephalography study.

Proudfoot M, Colclough GL, Quinn A, Wuu J, Talbot K, Benatar M, Nobre AC, Woolrich MW, Turner MR.

Neurology. 2018 Apr 17;90(16):e1418-e1424. doi: 10.1212/WNL.0000000000005333. Epub 2018 Mar 21.

4.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

PMID:
29566793
5.

Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report.

Pottier C, Rampersaud E, Baker M, Wu G, Wuu J, McCauley JL, Zuchner S, Schule R, Bermudez C, Hussain S, Cooley A, Wallace M, Zhang J, Taylor JP, Benatar M, Rademakers R.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):469-471. doi: 10.1080/21678421.2018.1452947. Epub 2018 Mar 20.

PMID:
29558868
6.

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.

Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D.

Neurology. 2018 Feb 13;90(7):e565-e574. doi: 10.1212/WNL.0000000000004960. Epub 2018 Jan 24.

7.

Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers.

Finch NA, Wang X, Baker MC, Heckman MG, Gendron TF, Bieniek KF, Wuu J, DeJesus-Hernandez M, Brown PH, Chew J, Jansen-West KR, Daughrity LM, Nicholson AM, Murray ME, Josephs KA, Parisi JE, Knopman DS, Petersen RC, Petrucelli L, Boeve BF, Graff-Radford NR, Asmann YW, Dickson DW, Benatar M, Bowser R, Boylan KB, Rademakers R, van Blitterswijk M.

Neurol Genet. 2017 Jun 7;3(4):e161. doi: 10.1212/NXG.0000000000000161. eCollection 2017 Aug.

8.

Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF; C9ORF72 Neurofilament Study Group, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, Pastor P, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Benatar M, Silani V, Glass JD, Floeter MK, Jeromin A, Boylan KB, Petrucelli L.

Ann Neurol. 2017 Jul;82(1):139-146. doi: 10.1002/ana.24980.

9.

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L.

Sci Transl Med. 2017 Mar 29;9(383). pii: eaai7866. doi: 10.1126/scitranslmed.aai7866.

10.

Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS.

Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, Schultz D, Benatar M, Rogers ML.

Neurology. 2017 Mar 21;88(12):1137-1143. doi: 10.1212/WNL.0000000000003741. Epub 2017 Feb 22.

11.

Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study.

Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Forsberg K, Baumann P, Pinto S, de Carvalho M, Hübers A, Nordin F, Ludolph AC, Weishaupt JH, Meyer T, Grehl T, Schweikert K, Weber M, Burkhardt C, Neuwirth C, Holmøy T, Morita M, Tysnes OB, Benatar M, Wuu J, Lange DJ, Bisgård C, Asgari N, Tarvainen I, Brännström T, Andersen PM.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):256-264. doi: 10.1080/21678421.2016.1262423. Epub 2016 Dec 12.

PMID:
27936955
12.

Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.

Proudfoot M, Rohenkohl G, Quinn A, Colclough GL, Wuu J, Talbot K, Woolrich MW, Benatar M, Nobre AC, Turner MR.

Hum Brain Mapp. 2017 Jan;38(1):237-254. doi: 10.1002/hbm.23357. Epub 2016 Sep 13.

13.

Presymptomatic ALS genetic counseling and testing: Experience and recommendations.

Benatar M, Stanislaw C, Reyes E, Hussain S, Cooley A, Fernandez MC, Dauphin DD, Michon SC, Andersen PM, Wuu J.

Neurology. 2016 Jun 14;86(24):2295-302. doi: 10.1212/WNL.0000000000002773. Epub 2016 May 18. Review.

14.

C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells.

Esanov R, Belle KC, van Blitterswijk M, Belzil VV, Rademakers R, Dickson DW, Petrucelli L, Boylan KB, Dykxhoorn DM, Wuu J, Benatar M, Wahlestedt C, Zeier Z.

Exp Neurol. 2016 Mar;277:171-177. doi: 10.1016/j.expneurol.2015.12.022. Epub 2015 Dec 31.

15.

Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk.

Menke RA, Proudfoot M, Wuu J, Andersen PM, Talbot K, Benatar M, Turner MR.

J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):580-8. doi: 10.1136/jnnp-2015-311945. Epub 2016 Jan 5.

16.

Bromodomain inhibitors regulate the C9ORF72 locus in ALS.

Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, Wahlestedt C.

Exp Neurol. 2015 Sep;271:241-50. doi: 10.1016/j.expneurol.2015.06.017. Epub 2015 Jun 20.

17.

Hippocampal endosomal, lysosomal, and autophagic dysregulation in mild cognitive impairment: correlation with aβ and tau pathology.

Perez SE, He B, Nadeem M, Wuu J, Ginsberg SD, Ikonomovic MD, Mufson EJ.

J Neuropathol Exp Neurol. 2015 Apr;74(4):345-58. doi: 10.1097/NEN.0000000000000179.

18.

Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Perez SE, He B, Nadeem M, Wuu J, Scheff SW, Abrahamson EE, Ikonomovic MD, Mufson EJ.

Biol Psychiatry. 2015 Apr 15;77(8):693-703. doi: 10.1016/j.biopsych.2013.12.016. Epub 2014 Jan 11.

19.

Motor neuron involvement in multisystem proteinopathy: implications for ALS.

Benatar M, Wuu J, Fernandez C, Weihl CC, Katzen H, Steele J, Oskarsson B, Taylor JP.

Neurology. 2013 May 14;80(20):1874-80. doi: 10.1212/WNL.0b013e3182929fc3. Epub 2013 May 1.

20.

Radioactivity inspection of Taiwan for food products imported from Japan after the Fukushima nuclear accident.

Chiu HS, Huang PJ, Wuu JL, Wang JJ.

Appl Radiat Isot. 2013 Nov;81:356-7. doi: 10.1016/j.apradiso.2013.03.009. Epub 2013 Mar 16.

PMID:
23583088
21.

Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosis.

Benatar M, Wuu J, Ravits J.

Muscle Nerve. 2013 May;47(5):629-31. doi: 10.1002/mus.23782. Epub 2013 Mar 15. No abstract available.

PMID:
23494825
22.

Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, Fritz J, Lah J, Ginsberg SD, Wuu J, Scheff SW.

J Neuropathol Exp Neurol. 2012 Nov;71(11):1018-29. doi: 10.1097/NEN.0b013e318272caab.

23.

Presymptomatic studies in ALS: rationale, challenges, and approach.

Benatar M, Wuu J.

Neurology. 2012 Oct 16;79(16):1732-9. doi: 10.1212/WNL.0b013e31826e9b1d. Review. No abstract available.

24.

Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains.

Sager KL, Wuu J, Herskowitz JH, Mufson EJ, Levey AI, Lah JJ.

PLoS One. 2012;7(8):e40527. doi: 10.1371/journal.pone.0040527. Epub 2012 Aug 21.

25.

Hippocampal drebrin loss in mild cognitive impairment.

Counts SE, He B, Nadeem M, Wuu J, Scheff SW, Mufson EJ.

Neurodegener Dis. 2012;10(1-4):216-9. doi: 10.1159/000333122. Epub 2012 Feb 4.

26.

Aberrant septin 11 is associated with sporadic frontotemporal lobar degeneration.

Gozal YM, Seyfried NT, Gearing M, Glass JD, Heilman CJ, Wuu J, Duong DM, Cheng D, Xia Q, Rees HD, Fritz JJ, Cooper DS, Peng J, Levey AI, Lah JJ.

Mol Neurodegener. 2011 Nov 29;6:82. doi: 10.1186/1750-1326-6-82.

27.

An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center.

Hanfelt JJ, Wuu J, Sollinger AB, Greenaway MC, Lah JJ, Levey AI, Goldstein FC.

Am J Geriatr Psychiatry. 2011 Nov;19(11):940-50. doi: 10.1097/JGP.0b013e31820ee9d2.

28.

Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI.

Am J Pathol. 2011 Nov;179(5):2533-50. doi: 10.1016/j.ajpath.2011.07.044. Epub 2011 Sep 23.

29.

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Hölttä-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chiò A, Restagno G, Borghero G, Sabatelli M; ITALSGEN Consortium, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ.

Neuron. 2011 Oct 20;72(2):257-68. doi: 10.1016/j.neuron.2011.09.010. Epub 2011 Sep 21.

30.

Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS.

Carew JD, Nair G, Andersen PM, Wuu J, Gronka S, Hu X, Benatar M.

Neurology. 2011 Oct 4;77(14):1370-5. doi: 10.1212/WNL.0b013e318231526a. Epub 2011 Sep 21.

31.

Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Wuu J, Mathis CA, Scheff SW, Mufson EJ, DeKosky ST.

Neurology. 2011 Jul 5;77(1):39-47. doi: 10.1212/WNL.0b013e3182231419. Epub 2011 Jun 22.

32.

Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Ginsberg SD, Mufson EJ, Alldred MJ, Counts SE, Wuu J, Nixon RA, Che S.

J Chem Neuroanat. 2011 Oct;42(2):102-10. doi: 10.1016/j.jchemneu.2011.05.012. Epub 2011 Jun 12.

33.

Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis.

Fanos JH, Gronka S, Wuu J, Stanislaw C, Andersen PM, Benatar M.

Genet Med. 2011 Apr;13(4):342-8. doi: 10.1097/GIM.0b013e318204d004.

34.

Exome sequencing reveals VCP mutations as a cause of familial ALS.

Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang YD, Calvo A, Mora G, Sabatelli M, Monsurrò MR, Battistini S, Salvi F, Spataro R, Sola P, Borghero G; ITALSGEN Consortium, Galassi G, Scholz SW, Taylor JP, Restagno G, Chiò A, Traynor BJ.

Neuron. 2010 Dec 9;68(5):857-64. doi: 10.1016/j.neuron.2010.11.036. Erratum in: Neuron. 2011 Jan 27;69(2):397.

35.

Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease.

Ginsberg SD, Mufson EJ, Counts SE, Wuu J, Alldred MJ, Nixon RA, Che S.

J Alzheimers Dis. 2010;22(2):631-9. doi: 10.3233/JAD-2010-101080.

36.

Preparing for a U.S. National ALS Registry: Lessons from a pilot project in the State of Georgia.

Benatar M, Wuu J, Usher S, Ward K.

Amyotroph Lateral Scler. 2011 Mar;12(2):130-5. doi: 10.3109/17482968.2010.515224. Epub 2010 Sep 15.

PMID:
20843169
37.

Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression.

Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, Wuu J, Chao MV, Mufson EJ, Nixon RA, Che S.

Biol Psychiatry. 2010 Nov 15;68(10):885-93. doi: 10.1016/j.biopsych.2010.05.030. Epub 2010 Jul 23.

38.

Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Overk CR, Felder CC, Tu Y, Schober DA, Bales KR, Wuu J, Mufson EJ.

J Chem Neuroanat. 2010 Sep;40(1):63-70. doi: 10.1016/j.jchemneu.2010.03.005. Epub 2010 Mar 27.

39.

Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease.

Mufson EJ, Wuu J, Counts SE, Nykjaer A.

Neurosci Lett. 2010 Mar 8;471(3):129-33. doi: 10.1016/j.neulet.2010.01.023. Epub 2010 Jan 18.

40.

Increased matrix metalloproteinase 9 activity in mild cognitive impairment.

Bruno MA, Mufson EJ, Wuu J, Cuello AC.

J Neuropathol Exp Neurol. 2009 Dec;68(12):1309-18. doi: 10.1097/NEN.0b013e3181c22569.

41.

Reference data for commonly used sensory and motor nerve conduction studies.

Benatar M, Wuu J, Peng L.

Muscle Nerve. 2009 Nov;40(5):772-94. doi: 10.1002/mus.21490.

PMID:
19827092
42.

Developing reference data for nerve conduction studies: an application of quantile regression.

Peng L, Wuu J, Benatar M.

Muscle Nerve. 2009 Nov;40(5):763-71. doi: 10.1002/mus.21489.

PMID:
19827091
43.

Cell-free synthesis of functional aquaporin Z in synthetic liposomes.

Hovijitra NT, Wuu JJ, Peaker B, Swartz JR.

Biotechnol Bioeng. 2009 Sep 1;104(1):40-9. doi: 10.1002/bit.22385.

PMID:
19557835
44.

Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.

Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST.

Arch Neurol. 2009 May;66(5):646-51. doi: 10.1001/archneurol.2009.46.

45.

A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy.

Kanner AM, Byrne R, Chicharro A, Wuu J, Frey M.

Neurology. 2009 Mar 3;72(9):793-9. doi: 10.1212/01.wnl.0000343850.85763.9c.

PMID:
19255406
46.

Clearance measurement of metal scraps for nuclear facility at INER in Taiwan.

Wei HJ, Tsai TL, Wang JJ, Chen IJ, Wuu JL, Wang TW.

Appl Radiat Isot. 2009 May;67(5):944-9. doi: 10.1016/j.apradiso.2009.01.080. Epub 2009 Jan 30.

PMID:
19243957
47.

Treatment of ocular symptoms in myasthenia gravis.

Bhanushali MJ, Wuu J, Benatar M.

Neurology. 2008 Oct 21;71(17):1335-41. doi: 10.1212/01.wnl.0000327669.75695.38.

PMID:
18936425
48.

An integrated cell-free metabolic platform for protein production and synthetic biology.

Jewett MC, Calhoun KA, Voloshin A, Wuu JJ, Swartz JR.

Mol Syst Biol. 2008;4:220. doi: 10.1038/msb.2008.57. Epub 2008 Oct 14.

49.

Characterization of potential outcome measures for future clinical trials in fragile X syndrome.

Berry-Kravis E, Sumis A, Kim OK, Lara R, Wuu J.

J Autism Dev Disord. 2008 Oct;38(9):1751-7. doi: 10.1007/s10803-008-0564-8. Epub 2008 Mar 28.

PMID:
18369716
50.

High yield cell-free production of integral membrane proteins without refolding or detergents.

Wuu JJ, Swartz JR.

Biochim Biophys Acta. 2008 May;1778(5):1237-50. doi: 10.1016/j.bbamem.2008.01.023. Epub 2008 Feb 11.

Supplemental Content

Support Center